Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-09-30 am EDT
9944.00 GBX   +0.11%
09/30AstraZeneca plc Announces Board Committee Changes
CI
09/30ASTRAZENECA PLC : Changes in management and corporate officers
CO
09/29Mayne pharma - appointment of chief executive officer and managing director
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK

08/16/2022 | 09:05am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.11% 9944 Delayed Quote.14.59%
GSK PLC -0.76% 1305.8 Delayed Quote.-20.55%
All news about ASTRAZENECA PLC
09/30AstraZeneca plc Announces Board Committee Changes
CI
09/30ASTRAZENECA PLC : Changes in management and corporate officers
CO
09/29Mayne pharma - appointment of chief executive officer and managing director
AQ
09/28Tezspire approved for a broad population of patients with severe asthma with no phenoty..
AQ
09/28Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neur..
AQ
09/28Tezspire approved in Japan for the treatment of severe asthma
AQ
09/28Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neur..
AQ
09/27BenevolentAI - Interim results for the six months ended 30 June 2022
AQ
09/27AstraZeneca Says Bronchial Asthma Treatment Approved in Japan
MT
09/27AstraZeneca-Merck's Rare Genetic Condition Medicine Gets Approval in Japan
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 343 M - -
Net income 2022 4 553 M - -
Net Debt 2022 24 544 M - -
P/E ratio 2022 39,5x
Yield 2022 2,67%
Capitalization 172 B 172 B -
EV / Sales 2022 4,43x
EV / Sales 2023 4,10x
Nbr of Employees 83 100
Free-Float 96,5%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 110,81 $
Average target price 141,32 $
Spread / Average Target 27,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC14.59%171 692
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296